DDInter1840 DDInter674
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate].
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eslicarbazepine
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eslicarbazepine
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine